Announced details
Development of a therapeutic drug for patients at risk of acute kidney injury following cardiovascular surgery
Contractual relationship for conducting TMS-008's clinical trial
Clinical trial site that obtained IRB approval. Location, representative, business activities, capital and year established: Not disclosed
There will be no impact on results for the fiscal year ending December 2026. The expenses for the current fiscal year required for this trial are included in the range of research and development expenses announced on 13 February 2026.
The company does not address Contract Value / Offering price.
Machado MN, et al. Rev Bras Cir Cardiovasc. 29: 299–307 (2014)
| Item | Details |
|---|---|
| Names of Products / Services Covered | TMS-008 |
| Counterparty | First clinical trial site (name not disclosed) |
| Counterparty overview | Clinical trial site that obtained IRB approval. Location, representative, business activities, capital and year established: Not disclosed |
| Relationship with the Company | Contractual relationship for conducting TMS-008's clinical trial |
| Contract Date | 18 November 2026 (the date the completion of the contract signing was announced; the contract signing date itself: Not disclosed) |
| Applicable area | Development of a therapeutic drug for patients at risk of acute kidney injury following cardiovascular surgery |
| Impact on Business Performance | There will be no impact on results for the fiscal year ending December 2026. The expenses for the current fiscal year required for this trial are included in the range of research and development expenses announced on 13 February 2026. |
| Source | Machado MN, et al. Rev Bras Cir Cardiovasc. 29: 299–307 (2014) |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To advance the procedures toward starting case enrollment in this trial, with the aim of enrolling the first subject and completing enrollment at an early stage.